The Patents Act, 1970 represents the cornerstone of India’s patent regime and seeks to strike a careful balance between the protection of intellectual property rights and the broader interests of society. While patents grant inventors exclusive rights over their inventions and provide incentives for innovation, the law also recognizes that these rights cannot operate in complete isolation from public welfare, national interest, healthcare accessibility, economic development, and technological progress. Consequently, the Patents Act contains several provisions designed to ensure that patent monopolies do not impede public access to essential technologies and products. Two particularly important mechanisms reflecting this balance are the provisions relating to patent acquisition by the government and the Bolar exception under Section 107A of the Act.
Although these provisions operate in different contexts, both are aimed at reconciling private patent rights with public interest objectives. Patent acquisition by the government empowers the State to acquire patents or patent applications under specific circumstances where public interest, national security, or governmental needs justify such intervention, while the Bolar Provision permits certain acts that would otherwise constitute patent infringement when undertaken for purposes related to obtaining regulatory approvals. Together, these provisions demonstrate the Indian patent system’s commitment to encouraging innovation while ensuring that patent protection does not become an obstacle to public welfare, technological dissemination, or access to essential products. Patent acquisition by the government is governed primarily by Chapter XIII of the Patents Act, 1970.
The rationale underlying these provisions is that certain inventions may possess such significance for national security, public administration, industrial development, or public welfare that governmental intervention becomes necessary. While patents are private property rights, they are not absolute rights. The State retains the authority to intervene in exceptional situations where the broader interests of society outweigh the exclusive rights granted to individual patent holders. Section 102 of the Patents Act empowers the Central Government to acquire a patent or a patent application by publishing a notification in the Official Gazette declaring that the invention is required for a public purpose. Upon publication of such notification, all rights in the patent or patent application vest in the government.
This provision effectively enables the government to become the owner of the patent, thereby acquiring complete control over the invention and its exploitation. The term “public purpose” is not exhaustively defined in the Act, allowing flexibility in addressing diverse circumstances such as national emergencies, defence requirements, public health crises, infrastructure development, technological advancement, or strategic industrial objectives. Once the government acquires a patent under Section 102, compensation is payable to the patent holder. The amount of compensation is determined either through agreement between the parties or, in the absence of agreement, by the High Court.
This requirement ensures that patent holders receive fair remuneration for the loss of their proprietary rights while enabling the government to secure access to technologies necessary for serving public interests. The concept of government acquisition of patents reflects the broader principle that intellectual property rights exist not only to reward inventors but also to contribute to social and economic development. In practice, the acquisition power is rarely exercised, but its existence serves as an important safeguard enabling governmental intervention in extraordinary circumstances. Closely related to government acquisition are provisions concerning secrecy directions and defence-related inventions.
Sections 35 to 42 of the Patents Act empower the government to impose secrecy directions on inventions relevant to national defence or security. Where an invention is considered important for defence purposes, the government may restrict publication and prohibit disclosure of the invention. Such measures prevent sensitive technologies from becoming publicly available in a manner that could compromise national security. These provisions highlight the importance of balancing intellectual property rights with broader strategic considerations.
Government acquisition and secrecy directions together form part of a broader framework through which the State may regulate patent rights in the public interest. Another significant mechanism reflecting the public interest orientation of the Patents Act is the Bolar Provision embodied in Section 107A. The Bolar exception constitutes one of the most important statutory defences against patent infringement and plays a particularly crucial role in the pharmaceutical and biotechnology industries. The provision derives its name from the United States case of Roche Products Inc. v. Bolar Pharmaceutical Co., where the court held that a generic pharmaceutical manufacturer’s use of a patented drug to conduct tests necessary for regulatory approval constituted patent infringement. In response to concerns that such a ruling would effectively extend patent monopolies beyond their statutory term, the United States enacted the Hatch-Waxman Act, introducing a legislative exception permitting activities reasonably related to obtaining regulatory approval. India incorporated a similar principle through Section 107A of the Patents Act.
The objective of the Bolar Provision is to ensure that generic manufacturers and other competitors can complete regulatory approval processes before patent expiry, thereby enabling immediate market entry once patent protection ends. Without such an exception, competitors would be forced to wait until patent expiry before commencing regulatory procedures, resulting in delays that would effectively prolong the patentee’s exclusivity. Section 107A(a) provides that any act of making, constructing, using, selling, or importing a patented invention solely for uses reasonably related to the development and submission of information required under any law in India or in any other country regulating the manufacture, use, sale, or import of any product shall not be considered infringement.
This provision is exceptionally broad and applies not only to pharmaceuticals but also to any patented invention requiring regulatory approval. The significance of the phrase “reasonably related” has been the subject of extensive judicial interpretation. Courts have generally adopted a purposive approach, recognizing that the exemption is intended to facilitate regulatory compliance rather than commercial exploitation. Activities such as bioequivalence studies, stability testing, clinical trials, data generation, and preparation of regulatory submissions typically fall within the scope of the exemption. However, activities undertaken primarily for commercial purposes rather than regulatory approval are unlikely to qualify for protection. One of the most important judicial decisions concerning the Bolar Provision is Bayer Intellectual Property GmbH v. Alembic Pharmaceuticals Ltd.
In this case, the Delhi High Court examined whether the manufacture and export of a patented pharmaceutical product for obtaining regulatory approval in foreign jurisdictions fell within the scope of Section 107A. Bayer argued that such activities exceeded the permissible limits of the Bolar exception and constituted infringement. Alembic contended that the exports were undertaken solely for generating information required by foreign regulatory authorities. The court held that the Bolar Provision should be interpreted in light of its legislative purpose and concluded that exports genuinely related to obtaining regulatory approvals could fall within the exemption. This judgment significantly broadened the practical utility of Section 107A and confirmed that the provision applies not only to domestic regulatory activities but also to regulatory processes in other countries.
Another notable decision is Merck Sharp and Dohme Corp. v. SMS Pharmaceuticals Ltd., where the Delhi High Court emphasized that the exemption protects activities reasonably related to regulatory approval but does not permit commercial exploitation of patented inventions. These decisions reflect the judiciary’s recognition of the need to balance patent rights with competition, public health, and technological dissemination. The Bolar Provision plays a particularly important role in the pharmaceutical sector because obtaining marketing approval for generic drugs often requires extensive testing, documentation, and regulatory review.
Such processes may take several years to complete. By permitting preparatory activities during the patent term, Section 107A ensures that generic products can enter the market immediately after patent expiry, thereby promoting competition and reducing healthcare costs. This objective aligns closely with India’s broader public health policies and its role as a major global supplier of affordable generic medicines. The provision also benefits other industries involving regulated products, including medical devices, agrochemicals, biotechnology products, and certain industrial technologies. From a policy perspective, the Bolar exception reflects the principle that patent protection should not unnecessarily delay access to competitive alternatives once exclusivity has expired.
It ensures that patent holders receive the full benefit of their statutory monopoly while preventing unintended extensions of that monopoly through regulatory barriers. The relationship between government acquisition provisions and the Bolar exception illustrates the broader philosophy underlying the Patents Act, 1970. Both mechanisms seek to balance private intellectual property rights with public interest considerations, albeit in different ways. Government acquisition provisions address situations where direct governmental intervention is necessary to secure access to important technologies for public purposes.
The Bolar exception, by contrast, facilitates market competition and regulatory preparedness without transferring ownership or directly interfering with patent rights. Together, these provisions demonstrate that patent law serves not only private economic interests but also broader societal objectives. Internationally, both government acquisition and regulatory exceptions are recognized under the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). TRIPS permits member states to adopt measures necessary to protect public health, promote technological dissemination, and address public interest concerns, provided such measures comply with international obligations.
The Bolar exception is widely regarded as consistent with Article 30 of TRIPS, which permits limited exceptions to patent rights that do not unreasonably conflict with the normal exploitation of patents or prejudice the legitimate interests of patent owners. Similarly, government acquisition mechanisms are generally viewed as legitimate exercises of sovereign authority when accompanied by appropriate compensation and procedural safeguards. The practical significance of these provisions has increased in recent years due to growing concerns regarding access to medicines, technological self-reliance, public health emergencies, and national security.
The COVID-19 pandemic highlighted the importance of legal mechanisms enabling governments to respond effectively to crises involving healthcare technologies, vaccines, medical equipment, and pharmaceutical products. Discussions concerning compulsory licensing, government use provisions, patent waivers, and technology transfer further underscored the need for flexible intellectual property frameworks capable of balancing innovation incentives with public welfare objectives. In India, where healthcare accessibility and affordable technology remain important policy priorities, provisions such as government acquisition and the Bolar exception continue to play a vital role in shaping the patent landscape. Businesses, innovators, and legal practitioners must understand these provisions not merely as limitations on patent rights but as integral components of a balanced intellectual property system designed to promote innovation while safeguarding societal interests.
In conclusion, patent acquisition by the government and the Bolar Provision under the Patents Act, 1970 represent two important mechanisms through which Indian patent law reconciles private intellectual property rights with public interest objectives. Government acquisition empowers the State to secure ownership of patents or patent applications for public purposes while ensuring fair compensation to patent holders, whereas the Bolar exception facilitates regulatory approval activities necessary for timely market entry of competing products after patent expiry. Both provisions reflect the principle that patent protection must operate within a broader framework of social welfare, public health, national security, and economic development. By balancing innovation incentives with accessibility and competition, these provisions contribute to a patent system that supports technological progress while remaining responsive to the needs of society, thereby reinforcing the fundamental objectives of intellectual property law in a modern and dynamic economy.
Leave a Reply